Cambio de paradigma en el EGFR mutado: desde las primeras mutaciones a las de resistencia - page 8

The ASPIRATION study

« PFS1 »

« PFS2 »

Parck, JAMA Oncol 2016

Erlotinib beyond RECIST PD improved 3.9 mo. the PFS

(from 11 mo. to 14.9 mo.) for tumours with common

EGFR

mutant

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6,7 9,10,11,12,13,14,15,16,17,18,...35